|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM367840855 |
| 003 |
DE-627 |
| 005 |
20240329000442.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240131s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.2144/btn-2023-0102
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1353.xml
|
| 035 |
|
|
|a (DE-627)NLM367840855
|
| 035 |
|
|
|a (NLM)38293767
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Machida, Kodai
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a High-throughput screening for a SARS-CoV-2 frameshifting inhibitor using a cell-free protein synthesis system
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 28.03.2024
|
| 500 |
|
|
|a Date Revised 28.03.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Programmed-1 ribosomal frameshifting (-1 PRF) is a translational mechanism adopted by some viruses, including SARS-CoV-2. To find a compound that can inhibit -1 PRF in SARS-CoV-2, we set up a high-throughput screening system using a HeLa cell extract-derived cell-free protein synthesis (CFPS) system. A total of 32,000 compounds were individually incubated with the CFPS system programmed with a -1 PRF-EGFP template. Several compounds were observed to decrease the -1 PRF-driven fluorescence, and one of them had some suppressive effect on -1 PRF of a SARS-CoV-2 genome sequence in transfected cells. Thus the CFPS system can be used as a tool for a high-throughput screening of chemicals
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
4 |
|a cell-free protein synthesis
|
| 650 |
|
4 |
|a drug discovery
|
| 650 |
|
4 |
|a programmed-1 ribosomal frameshifting
|
| 650 |
|
4 |
|a screening
|
| 700 |
1 |
|
|a Tanaka, Rin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Miki, Seraya
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Noseda, Shotaro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yuasa-Sunagawa, Mayumi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Imataka, Hiroaki
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t BioTechniques
|d 1988
|g 76(2024), 4 vom: 25. März, Seite 161-168
|w (DE-627)NLM012627046
|x 1940-9818
|7 nnns
|
| 773 |
1 |
8 |
|g volume:76
|g year:2024
|g number:4
|g day:25
|g month:03
|g pages:161-168
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.2144/btn-2023-0102
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_21
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_62
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_99
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_618
|
| 912 |
|
|
|a GBV_ILN_640
|
| 912 |
|
|
|a GBV_ILN_754
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2002
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2007
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2009
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2015
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 912 |
|
|
|a GBV_ILN_2023
|
| 912 |
|
|
|a GBV_ILN_2035
|
| 912 |
|
|
|a GBV_ILN_2040
|
| 912 |
|
|
|a GBV_ILN_2060
|
| 912 |
|
|
|a GBV_ILN_2099
|
| 912 |
|
|
|a GBV_ILN_2105
|
| 912 |
|
|
|a GBV_ILN_2121
|
| 912 |
|
|
|a GBV_ILN_2470
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 76
|j 2024
|e 4
|b 25
|c 03
|h 161-168
|